The distribution of BRAF gene fusions in solid tumors and response to targeted therapy

Although the BRAF V600E base substitution is an approved target for the BRAF inhibitors in melanoma, BRAF gene fusions have not been investigated as anticancer drug targets. In our study, a wide variety of tumors underwent comprehensive genomic profiling for hundreds of known cancer genes using the...

Descripción completa

Detalles Bibliográficos
Autores principales: Ross, Jeffrey S., Wang, Kai, Chmielecki, Juliann, Gay, Laurie, Johnson, Adrienne, Chudnovsky, Jacob, Yelensky, Roman, Lipson, Doron, Ali, Siraj M, Elvin, Julia A., Vergilio, Jo‐Anne, Roels, Steven, Miller, Vincent A, Nakamura, Brooke N., Gray, Adam, Wong, Michael K, Stephens, Philip J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Cancer Genetics and Epigenetics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049644/
https://www.ncbi.nlm.nih.gov/pubmed/26314551
http://dx.doi.org/10.1002/ijc.29825

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5049644/
https://www.ncbi.nlm.nih.gov/pubmed/26314551
http://dx.doi.org/10.1002/ijc.29825

Ejemplares similares